Novacyt is scheduled to launch two PathFlow Covid-19 antigen lateral flow tests (LFTs), strengthening the company’s Covid-19 testing portfolio and expanding its footing in point-of-care solutions. The company is expected to initially target private market opportunities for these LFTs through its own distribution network. The new PathFlow Covid-19 antigen tests are small, instrument-free and enable safe sample collection, testing, reading and disposal by healthcare professionals or patients at their homes.

Avacta Group, a diagnostics and innovative cancer therapies developer, announced that a study found its AffiDX® antigen lateral flow test can successfully detect the Delta variant in clinical Covid-19 samples. This test also seemed to beat two other lateral flow antigen tests that are commercially available in Europe. Clinical data for Avacta’s test found it to have 100% sensitivity in detecting infectious individuals with viral loads of Ct<27 via a PCR test, where patients are considered to be contagious.

BGI Americas, a diagnostic testing solutions provider, has entered into a partnership with Advaite, a biotech company, and announced the launch of, a hub for diagnostics companies looking for partnerships based on licensing, distribution agreements and original equipment manufacturers. The partnership is expected to add Advaite’s RapCov rapid Covid-19 test to BGI’s portfolio of diagnostic testing solutions and combine Advaite’s handheld test with its real-time fluorescent RT-PCR kit for detecting SARS-CoV-2.